O’Melveny Represents OrbusNeich Medical Group in its US$200 million Series A and A-2 Fundraising Rounds
August 30, 2021
FOR IMMEDIATE RELEASE
HONG KONG—AUGUST 30, 2021—O’Melveny recently represented OrbusNeich Medical Group Ltd., a leading medical device manufacturer headquartered in Hong Kong and specialising in the design, production and sales of innovative products for vascular intervention, in its over US$200 million Series A and A-2 Financing Rounds.
The participating investors include Shenzhen Capital Group (together with its healthcare investment fund, Red Earth Healthcare Investment Fund), CCB International, CICC Biomedical Fund L.P. of CICC Capital, China Merchants Securities Investment, Shenzhen Share Capital Healthcare Fund and other well-known family offices.
The proceeds raised will enable OrbusNeich to further invest in research and development activities and accelerate its growth in new and existing product areas, both in Greater China and overseas.
The O’Melveny team was led by Hong Kong corporate partner Edwin Kwok, and included senior legal consultant Aaron Xin, associate Qianru Hong, counsel Wendy Kan, and associate Hilda Leung.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com or learn more in our firm at-a-glance, year-end highlights, and on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
Contact:
Christopher Rieck
O’Melveny & Myers LLP
+1 212 326 2218
crieck@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com